• Policy
• Reimbursement priorities in ultra-high-priced one-shot Txs
• by Lee, Tak-Sun Mar 31, 2022 05:57am

• Policy
• Multidrug-resistant ‘Zavicefta’ applies for approval
• by Lee, Hye-Kyung Mar 29, 2022 05:54am

• Policy
• Will the migraine tx Reyvow step on the same track
• by Lee, Tak-Sun Mar 29, 2022 05:54am

• Policy
• BMS acute myeloid leukemia tx Onureg was approved
• by Lee, Hye-Kyung Mar 29, 2022 05:54am

• Policy
• Will the separation of the Ministry of Health be promoted?
• by Lee, Jeong-Hwan Mar 28, 2022 06:10am

• Policy
• Govn’t to introduce 460,000 courses of oral COVID-19 drugs
• by Kim, Jung-Ju Mar 28, 2022 06:10am

• Policy
• The gov's all-out efforts to promote EUA for overseas drugs
• by Lee, Jeong-Hwan Mar 28, 2022 06:10am

• Policy
• Kymriah's benefit standard has been established
• by Lee, Tak-Sun Mar 25, 2022 05:48am

• Policy
• Yoon’s transition team prepares for digital platform govnt
• by Lee, Jeong-Hwan Mar 25, 2022 05:48am

• Policy
• Corona tx Largevrio has been urgently approved
• by Lee, Hye-Kyung Mar 24, 2022 05:54am